{"url_path":"/sec/cprx/8-k/2026-06-30/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-290768-index.html","accession_number":"0001193125-26-290768","cik":"0001369568","ticker":"CPRX","issuer_name":"CATALYST PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-290768-index.html","primary_entity_key":"0001369568","primary_entity_name":"CATALYST PHARMACEUTICALS, INC."},"word_count":39,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events\n\nOn June 30, 2026, the Company issued a press release announcing topline results from a two-part Phase 1 clinical study of AGAMREE (vamorolone). A copy of the press release is attached hereto as Exhibit 99.1."}